News

The Astellas dermatology portfolio consists of prescription and over-the-counter products, including Protopic, Locoid and Locobase, and Zineryt to treat eczema, acne and skin infections. The transaction, which is

NGP 555 is a first in class small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in

US-based Ocata develops and commercializes regenerative ophthalmology therapeutics. The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involve development of therapies to treat

Cotellic and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cotellic is Genentech’s seventh new medicine approved by the FDA in the past five

MRL Ventures, a venture fund of Merck, and JAFCO led the Series C preferred stock financing round. Brace Pharma Capital and MP Healthcare Venture Management were the other

As company spokesperson, Michael Thompson, noted, Nitrosolution first launched its original nitric oxide booster product Nitroxyl about 2 years ago. While Nitroxyl is designed for people over the

TaNeDS, which began in 2011 as part of Daiichi Sankyo’s open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon

The facility has been approved by the Swiss Agency for Therapeutic Products ("Swissmedic"), the Swiss equivalent to the US FDA. Stemedica has fully executed the transfer of its

This study is a collaborative effort between MediciNova and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital’s (MGH) Neurological Clinical Research Institute (NCRI) and